Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results

Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results

March 6, 2014

WATERTOWN, Mass.--(BUSINESS WIRE)--March 06, 2014-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.

Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results

Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results

March 5, 2014

 - Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 -

- Phase 3 trial of RPC1063 in relapsing multiple sclerosis has begun enrolling patients -

- Top-line data from Phase 2 trial of RPC1063 in ulcerative colitis expected in mid-2014 - 

Moderna Appoints Biotechnology Investment Banking Veteran Lorence Kim as Chief Financial Officer

Moderna Appoints Biotechnology Investment Banking Veteran Lorence Kim as Chief Financial Officer

March 6, 2014

CAMBRIDGE, Mass.March 6, 2014 /PRNewswire/ -- Moderna Therapeutics, the p

Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005

Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005

March 4, 2014

Patient Randomization and Dosing Underway in Allergic Conjunctivitis;

BIND Therapeutics Promotes Key Executives: Organization Positioned for Continued Growth

BIND Therapeutics Promotes Key Executives: Organization Positioned for Continued Growth

March 3, 2014

Appoints Andrew Hirsch as Chief Operating Officer and Jeff Hrkach as Chief Technology Officer

Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors

Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors

March 3, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Paul Chaney, President and Chief Executive Officer of PanOptica, Inc., to the Company's board of directors.

Joule Appoints David Anton Chief Technology Officer

Joule Appoints David Anton Chief Technology Officer

February 28, 2014

Bedford, MA – February 28, 2014 –Joule today announced the appointment of David Anton as Executive Vice President and Chief Technology Officer. In this newly-created role, Dr. Anton will lead the transition of Joule’s CO2-to-fuels technology into a commercial reality. He brings nearly 30 years of relevant experience to the company, including prior technology and business leadership roles at DuPont and Codexis.

Joule Names Paul Snaith as New President and CEO

Joule Names Paul Snaith as New President and CEO

February 20, 2014

Bedford, MA – February 20, 2014 – Joule today announced the appointment of Paul Snaith as President and Chief Executive Officer, following his most recent post as Chief Operating Officer. He assumes the role from Noubar Afeyan, Executive Chairman and Founder of Joule, who had been serving as interim CEO.

Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease

Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease

February 18, 2014

Patient Randomization and Dosing Underway

Pronutria® Announces Launch of Two Clinical Trials

Pronutria® Announces Launch of Two Clinical Trials

February 13, 2014

Closes $12.25 Million in Series B Financing to Advance ProNutrein™ Product Candidates